Clinical Trials Browser

Sunitinib × Genitourinary × Clear all

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT02853331 2026-02-02

KEYNOTE-426

Phase 3 Completed

861 enrolled 24 charts 1 FDA

Carcinoma, Renal Cell

NCT03091192 2026-01-23

Savolitinib vs. Sunitinib in MET-driven PRCC.

Phase 3 Active not recruiting

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT06726421 2026-01-15

STROKER

Phase 3 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03541902 2026-01-09

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Urologic Neoplasms

NCT00329043 2025-12-26

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT00715442 2025-12-23

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT04394975 2025-11-28

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Phase 3 Completed

Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1

NCT07165418 2025-09-10

A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI

Phase 3 Not yet recruiting

Carcinoma, Renal Cell

NCT00930033 2025-09-05

CARMENA

Phase 3 Completed

Carcinoma, Renal Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

Phase 3 Completed

886 enrolled 37 charts 1 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT03260894 2025-07-29

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Phase 3 Completed

129 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02231749 2025-06-26

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase 3 Completed

1,390 enrolled 18 charts 1 FDA

Carcinoma, Renal Cell

NCT03141177 2025-06-06

CheckMate 9ER

Phase 3 Active not recruiting

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT05043090 2025-05-08

SAMETA

Phase 3 Active not recruiting

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT00720941 2025-03-30

COMPARZ

Phase 3 Completed

1,110 enrolled 27 charts

Carcinoma, Renal Cell

NCT01147822 2025-03-28

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Phase 2 Completed

367 enrolled 14 charts

Carcinoma, Renal Cell

NCT06222593 2025-02-17

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT02761057 2025-01-13

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Phase 2 Completed

152 enrolled 19 charts

Carcinoma, Renal Cell

NCT03109015 2024-10-08

ASSET

Phase 2 Completed

7 enrolled 18 charts

Carcinoma, Renal Cell

NCT05745142 2024-08-05

A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

376 enrolled 17 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT03905889 2024-06-25

A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

Phase 1 Terminated

Carcinoma, Renal Cell

NCT03140176 2024-05-10

OPTIMISE

77 enrolled 34 charts

Carcinoma, Renal Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05949424 2023-11-29

OPTI-DOSE

Phase 4 Unknown

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT01517243 2023-09-21

Phase II Study of Alternating Sunitinib and Temsirolimus

Phase 2 Completed

37 enrolled 13 charts

Carcinoma, Renal Cell

NCT01164228 2023-06-15

Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery

Phase 2 Completed

87 enrolled 11 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00716625 2023-05-03

Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)

1,674 enrolled 17 charts

Carcinoma, Renal Cell

NCT04175262 2023-05-03

Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

102 enrolled 23 charts

Carcinoma, Renal Cell

NCT05816642 2023-04-18

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Phase NA Unknown

Carcinoma, Renal Cell

NCT03729245 2023-04-11

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Phase 3 Terminated

623 enrolled 14 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05800106 2023-04-10

A Bioequivalence Study of Sunitinib Malate Capsules.

Phase 1 Completed

GastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Adenoma, Islet Cell, Gastrointestinal Stromal Tumors

NCT04076787 2023-04-06

Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

1,769 enrolled 12 charts

Carcinoma, Renal Cell

NCT02420821 2023-01-30

IMmotion151

Phase 3 Completed

915 enrolled 40 charts

Carcinoma, Renal Cell

NCT00520533 2022-10-12

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Phase 1 Terminated

8 enrolled 18 charts

Carcinoma, Renal Cell, Mycobacterium Infections, Nontuberculous

NCT02432846 2022-08-22

MERECA

Phase 2 Completed

88 enrolled 23 charts

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT01664182 2022-06-07

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Phase 2 Completed

41 enrolled 13 charts

Carcinoma, Renal Cell

NCT04115189 2022-05-10

A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)

57 enrolled 35 charts

Carcinoma, Renal Cell

NCT03035630 2022-02-15

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Phase 2 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01472081 2021-12-02

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Phase 1 Completed

194 enrolled 18 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02689167 2021-11-29

SURF

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT02959554 2021-09-08

NIVOSWITCH

Phase 2 Terminated

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT01185366 2021-04-28

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Phase 2 Terminated

73 enrolled 17 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00853125 2021-04-27

Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Phase 2 Terminated

10 enrolled 8 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02960906 2021-04-26

BIONIKK

Phase 2 Completed

Clear-cell metastatic renal cell carcinoma

NCT00541008 2021-02-21

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

Phase 2 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01835158 2021-02-11

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Phase 2 Completed

157 enrolled 10 charts 1 FDA

Carcinoma, Renal Cell

NCT02555748 2021-01-12

SUP-R

Phase 4 Completed

Carcinoma, Renal Cell

NCT03066427 2020-11-13

INMUNOSUN

Phase 2 Completed

Carcinoma, Renal Cell

NCT01673386 2020-10-27

TAURUS

Phase 2 Terminated

58 enrolled 7 charts

Carcinoma, Renal Cell